Related references
Note: Only part of the references are listed.Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE
Herbert Struemper et al.
LUPUS SCIENCE & MEDICINE (2022)
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis
Brad H. Rovin et al.
KIDNEY INTERNATIONAL (2022)
Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus
Ellen Ginzler et al.
ARTHRITIS & RHEUMATOLOGY (2022)
Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme
Toni Maslen et al.
LUPUS SCIENCE & MEDICINE (2021)
Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries?
Raul Cortes Verdu et al.
RHEUMATOLOGY (2020)
Systemic lupus erythematosus 2020
Javier Narvaez
MEDICINA CLINICA (2020)
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Richard Furie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Comprehensive Review of Biological Agents for Lupus: Beyond Single Target
Bingyi Yang et al.
FRONTIERS IN IMMUNOLOGY (2020)
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
Fengchun Zhang et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
Joan T. Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study
Yoshiya Tanaka et al.
MODERN RHEUMATOLOGY (2017)
Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL
Caroline Gordon et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials
Megan E. B. Clowse et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
William Stohl et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
J. T. Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
D. A. Isenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials
Michelle A. Petri et al.
ARTHRITIS AND RHEUMATISM (2013)
Comparison of Alternative Primary Outcome Measures for Use in Lupus Nephritis Clinical Trials
David Wofsy et al.
ARTHRITIS AND RHEUMATISM (2013)
Emerging and critical issues in the pathogenesis of lupus
Mariele Gatto et al.
AUTOIMMUNITY REVIEWS (2013)
Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis
R. J. Davies et al.
LUPUS (2013)
B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design
Venkat Reddy et al.
ARTHRITIS RESEARCH & THERAPY (2013)
Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months
Zahi Touma et al.
RHEUMATOLOGY (2012)
The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus - Findings of a prospective, randomized, double-blind, placebo-controlled trial
Chung-E Tseng et al.
ARTHRITIS AND RHEUMATISM (2006)
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial
C Grigor et al.
LANCET (2004)
Share Paper
